A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of SR57746A in patients with mild-to-moderate dementia of the Alzheimer's type.
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Xaliproden (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- 22 Oct 2005 New trial record.